HC Pub.: 091086 (January 2011)
This HTML document is not a form. Its purpose is to display the information as found on the form for viewing purposes only. If you wish to use the form, you must use the alternate format below.
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Report of suspected adverse reaction to marketed health products
in Canada.
Completed forms should be faxed to: 613-957-0335 or mailed to:
Canada Vigilance Program
Marketed Health Products Directorate
Health Canada
Postal Locator 0701E
Ottawa, Ontario K1A 0K9
Submission of a report does not constitute an admission that medical personnel or the health product caused or contributed to the adverse reaction.
For further information on adverse reaction reporting by Market Authorization Holders (MAHs) and source establishments, please refer to:
This section must be completed by the market authorization holder (MAH), or the source establishment (for cells, tissues and organs).
A1. Report Source:
Indicate the source of the report (from where the information originated). For literature sources, provide the full literature citation in box C6. Check "Not Available to MAH/Unknown" if the initial reporter did not specify the report source. Select "Other" to indicate that the report source is known, but does not fit into one of the categories provided.
A2. Reporter Qualification:
Indicate the type of reporter who initially reported the adverse reaction (AR) to the MAH or source establishment.
A3. Reporter Also Sent Report to the Canada Vigilance Program:
Indicate whether the initial reporter also reported the AR to the Canada Vigilance Program.
A4. MAH/Source Establishment Contact Office:
Enter the full name, civic address, and telephone and facsimile numbers of the MAH or source establishment. Include a contact name. For source establishments, include the establishment registration number.
A5. MAH/Source Establishment Report No.:
Indicate the MAH's or source establishment's identification number for the case. For follow-up reports, the report number should be the same as the number assigned to the initial report.
A6. Type of Report:
A7. Date of Most Recent Information Received by MAH/Source Establishment:
Indicate the date when the MAH or source establishment received the information for this report.
A8. Date of this Report:
Indicate the date that this form was completed by the MAH or source establishment.
B1. Unique Identifier:
Provide a patient identifier in order to readily locate the case for follow-up purposes. Do not use the patient's name or initials.
B2. Age at Time of Reaction:
Provide the patient's age at the time of reaction.
B3. Sex:
Enter the patient's gender.
B4. Height:
Enter the patient's height, in centimetres (cm).
B5. Weight:
Enter the patient's weight, in kilograms (kg).
C1. Country in which Reaction Occurred:
Indicate the country where the reaction took place.
C2. Date of Reaction:
Provide the date of onset of the adverse reaction.
C3. Serious Report:
Indicate if the report is serious.
C4. Criteria for Report Seriousness:
Check all boxes that apply to the definition of a serious adverse reaction per the Food and Drug Regulations (C.R.C., c.870), the Natural Health Products Regulations (SOR/2003-196), and the Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007-118).
C5. Outcome:
Indicate the outcome of the adverse reaction.
C6. Describe the Reaction:
Provide a full description of the reaction(s) (e.g., body site and severity) and all relevant clinical information (medical status prior to the event, reported signs and/or symptoms, differential diagnosis for the event in question, clinical course, etc.).
C7. Relevant Tests/Laboratory Data:
Provide all appropriate information, including relevant negative tests and laboratory findings.
C8. Other Relevant History, Including Pre-existing Medical Conditions:
If available, provide information on the patient's history (e.g., race, allergies, pregnancy history, smoking and alcohol use, drug abuse) and other conditions known in the patient.
Up to two suspected health products may be reported on one form. Attach additional forms if there were more than two suspected health products for the reported AR.
D1, D2 Suspected Health Product Name:
For each suspected product, provide the product name, check the box that applies to the type of health product, and provide the additional information below.
D.i) Dose, Frequency & Route Used:
Describe how the product was used by the patient. For cells, tissues and organs, this box is only applicable to cells.
D.ii) Therapy Dates:
D.iii) Indication for Use of Suspected Health Product:
D.iv) Reaction Abated After Discontinuation or Dose Reduced:
D.v) Reaction Reappeared after Reintroduction:
D.vi) Lot #:
If known, indicate the lot number(s) of the suspected health product.
D.vii) Expiry Date:
If known, indicate the expiry date. For cells, tissues and organs, provide the date of expiration on the label, if any.
D3. Concomitant Health Products:
List and provide therapy dates for any other health products (drugs, biologics, including cells, tissues and organs, radiopharmaceuticals, natural health products, etc.) that the patient was using at the time of the event. Do not include health products used to treat the event.
D4. Treatment of the Adverse Reaction:
Describe the treatment of the adverse reaction, including other health products and/or therapies.
Canada Vigilance Program
Protected Bada Secretariat Government Security Policy
(when completed)
Mandatory fields are indicated by a ![]()
A. Reporter Information
(Must be completed by the Market Authorization Holder (MAH) or the Source Establishment)
B. Patient Information
Privacy Notice Statement: For the purposes of the Canada Vigilance Adverse Reaction Monitoring Program, information related to the identity of the patient and/or reporter will be protected as personal information under the Privacy Act, including in cases of an access to information request. For details with regard to personal information collected under this program, visit the Personal Information Bank; Health Canada; Health Products and Food Branch; Branch Incident Reporting System; PIB# PPU 088 at:
Institution-Specific Personal Information Banks.
C. Adverse Reaction
D. Health Product(s)
If more than two health products are suspected, attach additional sheets.
Use this form to report suspected adverse reactions to pharmaceuticals, biologics (including biotechnology products, fractionated blood products and vaccines), natural health products, radiopharmaceuticals or human cells, tissues or organs.
As per the Treasury Board of Canada Secretariat Government Security Policy